Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119296 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29401915 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL2307496 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29383465 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL3732490 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3MDM2PPARA | |
| SCHEMBL3732493 | 0.97 | MDM4 (0.54) | MDM4TP53CASP3MDM2PPARA | |
| SCHEMBL119455 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL1228254 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL118169 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30291593 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-112159461-A | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-101284863-B | Preparation method of solid phase synthesis cetrorelix | GL BIOCHEM SHANGHAI LTD | 2010-11-03 | — | — | CN | claimed |
| CN-101284863-A | Preparation method of solid phase synthesis cetrorelix | GL BIOCHEM SHANGHAI LTD (CN) | 2008-10-15 | — | — | CN | claimed |
| US-12215069-B2 | Sirtuin modulating compounds and applications thereof | CODAGEN BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114920804-B | Cetrorelix synthesis process capable of being directly used for pilot scale amplification | 厦门胜泽泰医药科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240228432-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | CODAGEN BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228432-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | CODAGEN BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228431-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | CODAGEN BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228431-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | CODAGEN BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12012370-B1 | Sirtuin modulating compounds and applications thereof | CODAGEN BIOSCIENCES, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-1280801-B1 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-07 | — | — | EP | disclosed |
| CN-1543461-A | Melanocortin receptor ligands | — | 2004-11-03 | — | — | CN | disclosed |
| US-6784298-B2 | 2-((3-CYCLOHEXYL-2-(2,5-DIOXO-4-(THIOPHEN-2-YL)METHYLIMIDA-ZOL IDIN-1-YL)PROPANOYL)AMINO) THIAZOLE-4-CARBOXYLIC ACID METHYL ESTER, E.G.; ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS; A GLUCOSE SENSOR IN BETA-CELLS AND HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| US-20030225286-A1 | Hydantoin-containing glucokinase activators | GOODNOW ROBERT ALAN (US) | 2003-12-04 | — | — | US | disclosed |
| US-6583288-B2 | (S,S)-2-((2-(4-(cyclohexyl)methyl-2,5-dioxoimidazolidin-1-yl)-3 -cyclopentylpropanoyl) amino)thiazole-4-carboxylic acid, methyl ester for example; for treatment of diabetes | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1280801-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001083478-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215069-B2 | Sirtuin modulating compounds and applications thereof | SIRT1, SIRT2, SIRT3 | MDM4 4604/4885TP53 1791/4885CASP3 3096/4885 |
| US-20240228432-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | SIRT1, SIRT2, SIRT3 | MDM4 4604/4885TP53 1791/4885CASP3 3096/4885 |
| US-20030225286-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | MDM4 4717/4885TP53 4711/4885CASP3 1204/4885 |
| US-20240228431-A1 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | SIRT1, SIRT2, SIRT3 | MDM4 4604/4885TP53 1791/4885CASP3 3096/4885 |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | MDM4 4717/4885TP53 4711/4885CASP3 1204/4885 |
| US-12012370-B1 | Sirtuin modulating compounds and applications thereof | SIRT1, SIRT2, SIRT3 | MDM4 4604/4885TP53 1791/4885CASP3 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.